These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29580419)

  • 1. Redox-sensitive nanoparticles based on 4-aminothiophenol-carboxymethyl inulin conjugate for budesonide delivery in inflammatory bowel diseases.
    Sun Q; Luan L; Arif M; Li J; Dong QJ; Gao Y; Chi Z; Liu CG
    Carbohydr Polym; 2018 Jun; 189():352-359. PubMed ID: 29580419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budesonide Loaded PLGA Nanoparticles for Targeting the Inflamed Intestinal Mucosa--Pharmaceutical Characterization and Fluorescence Imaging.
    Ali H; Weigmann B; Collnot EM; Khan SA; Windbergs M; Lehr CM
    Pharm Res; 2016 May; 33(5):1085-92. PubMed ID: 26718953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases.
    Ali H; Weigmann B; Neurath MF; Collnot EM; Windbergs M; Lehr CM
    J Control Release; 2014 Jun; 183():167-77. PubMed ID: 24685705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy.
    Naeem M; Choi M; Cao J; Lee Y; Ikram M; Yoon S; Lee J; Moon HR; Kim MS; Jung Y; Yoo JW
    Drug Des Devel Ther; 2015; 9():3789-99. PubMed ID: 26229440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophages-targeting mannosylated nanoparticles based on inulin for the treatment of inflammatory bowel disease (IBD).
    Sun Q; Arif M; Chi Z; Li G; Liu CG
    Int J Biol Macromol; 2021 Feb; 169():206-215. PubMed ID: 33340633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and in vitro characterization of multistage silicon-PLGA budesonide particles for inflammatory bowel disease.
    Leonard F; Srinivasan S; Liu X; Collnot EM; Ferrari M; Lehr CM; Godin B
    Eur J Pharm Biopharm; 2020 Jun; 151():61-72. PubMed ID: 32283213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Nanoparticle Morphology on Enhancing Delivery of Budesonide for Treatment of Inflammatory Bowel Disease.
    Li Q; Liu W; Liu K; Dong Z; Kong W; Lu X; Wei Y; Wu W; Yang J; Qi J
    ACS Appl Mater Interfaces; 2024 Jul; 16(26):33081-33092. PubMed ID: 38888094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smart Responsive Quercetin-Conjugated Glycol Chitosan Prodrug Micelles for Treatment of Inflammatory Bowel Diseases.
    Shen C; Zhao L; Du X; Tian J; Yuan Y; Jia M; He Y; Zeng R; Qiao R; Li C
    Mol Pharm; 2021 Mar; 18(3):1419-1430. PubMed ID: 33522827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hierarchical structured and programmed vehicles deliver drugs locally to inflamed sites of intestine.
    Li W; Li Y; Liu Z; Kerdsakundee N; Zhang M; Zhang F; Liu X; Bauleth-Ramos T; Lian W; Mäkilä E; Kemell M; Ding Y; Sarmento B; Wiwattanapatapee R; Salonen J; Zhang H; Hirvonen JT; Liu D; Deng X; Santos HA
    Biomaterials; 2018 Dec; 185():322-332. PubMed ID: 30267958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted delivery of budesonide in acetic acid induced colitis: impact on miR-21 and E-cadherin expression.
    Seoudi SS; Allam EA; El-Kamel AH; Elkafrawy H; El-Moslemany RM
    Drug Deliv Transl Res; 2023 Nov; 13(11):2930-2947. PubMed ID: 37184747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. pH/redox responsive core cross-linked nanoparticles from thiolated carboxymethyl chitosan for in vitro release study of methotrexate.
    Gao C; Liu T; Dang Y; Yu Z; Wang W; Guo J; Zhang X; He G; Zheng H; Yin Y; Kong X
    Carbohydr Polym; 2014 Oct; 111():964-70. PubMed ID: 25037437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Self assembled hyaluronic acid nanoparticles as a potential carrier for targeting the inflamed intestinal mucosa.
    Vafaei SY; Esmaeili M; Amini M; Atyabi F; Ostad SN; Dinarvand R
    Carbohydr Polym; 2016 Jun; 144():371-81. PubMed ID: 27083829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and characterization of pH-sensitive nanoparticles of budesonide for the treatment of ulcerative colitis.
    Zhou H; Qian H
    Drug Des Devel Ther; 2018; 12():2601-2609. PubMed ID: 30174414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme/pH dual sensitive polymeric nanoparticles for targeted drug delivery to the inflamed colon.
    Naeem M; Kim W; Cao J; Jung Y; Yoo JW
    Colloids Surf B Biointerfaces; 2014 Nov; 123():271-8. PubMed ID: 25266978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease.
    Beloqui A; Coco R; Memvanga PB; Ucakar B; des Rieux A; Préat V
    Int J Pharm; 2014 Oct; 473(1-2):203-12. PubMed ID: 25014369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surface engineered lipid nanoparticle-mediated site-specific drug delivery system for the treatment of inflammatory bowel disease.
    Sinhmar GK; Shah NN; Rawal SU; Chokshi NV; Khatri HN; Patel BM; Patel MM
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):565-578. PubMed ID: 29661024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced therapeutic efficacy of budesonide in experimental colitis with enzyme/pH dual-sensitive polymeric nanoparticles.
    Naeem M; Cao J; Choi M; Kim WS; Moon HR; Lee BL; Kim MS; Jung Y; Yoo JW
    Int J Nanomedicine; 2015; 10():4565-80. PubMed ID: 26213469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease.
    Date AA; Halpert G; Babu T; Ortiz J; Kanvinde P; Dimitrion P; Narayan J; Zierden H; Betageri K; Musmanno O; Wiegand H; Huang X; Gumber S; Hanes J; Ensign LM
    Biomaterials; 2018 Dec; 185():97-105. PubMed ID: 30236840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of budesonide-loaded mesoporous silica microparticles capped with a bulky azo derivative in rats with TNBS-induced colitis.
    Ferri D; Costero AM; Gaviña P; Parra M; Merino V; Teruel AH; Sancenón F; Martínez-Máñez R
    Int J Pharm; 2019 Apr; 561():93-101. PubMed ID: 30817986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A self-assembled, ROS-responsive Janus-prodrug for targeted therapy of inflammatory bowel disease.
    Li S; Xie A; Li H; Zou X; Zhang Q
    J Control Release; 2019 Dec; 316():66-78. PubMed ID: 31682913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.